John Ayanoglou - Biotricity Chief Officer

Summary

Executive

Mr. John Ayanoglou is Chief Financial Officer of the company. He has served as Chief Financial Officer of four financial services firms, three of which were publiclylisted companies. Mr. John Ayanoglou is Chief Financial Officer of the company. He currently serves as a director of Build Capital since October 2017. Prior to that, from October 2011 through October 26, 2017, Mr. Ayanoglou served as Executive Vice President of Build Capital. Prior to this, from May 2008 through September 2011, he served as Chief Financial Officer and Senior Vice President of Equitable Group Inc. and its whollyowned, OSFIregulated subsidiary, Equitable Bank. Mr. Ayanoglou transitioned to Equitable after serving as CFO, Vice President and Corporationrationrate Secretary of Xceed Mortgage Corporation, from August 2000 through May 2008, where he worked with an executive team that managed through performance standards, used focused strategic planning processes and 360 degree feedback loops. Mr. Ayanoglou has extensive experience in business consolidations, operating systems implementations and audit of integrated processes and systems since 2017.

Age	58
Tenure	8 years
Professional Marks	CPA
Phone	(800) 590-4155
Web	https://www.biotricity.com

Ayanoglou has counseled management on techniques to mitigate risks and establish more efficient, effective operations. During his career, Mr. Ayanoglou has kept pace with the rapid escalation of regulatory, public reporting and corporate governance requirements, which have characterized and shaped his responsibilities as CFO. He is a chartered accountant and a member of CPA Canada, Financial Executives International and has his ICD.D designation from the Institute of Corporationrationrationrate Directors at the Rotman School of Business.

John Ayanoglou Latest Insider Activity

Tracking and analyzing the buying and selling activities of John Ayanoglou against Biotricity stock is an integral part of due diligence when investing in Biotricity. John Ayanoglou insider activity provides valuable insight into whether Biotricity is net buyers or sellers over its current business cycle. Note, Biotricity insiders must abide by specific rules, including filing SEC forms every time they buy or sell Biotricity'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.

		John Ayanoglou over three months ago Acquisition by John Ayanoglou of 50000 shares of Biotricity at 0.73 subject to Rule 16b-3
		John Ayanoglou over a year ago Acquisition by John Ayanoglou of 50000 shares of Biotricity subject to Rule 16b-3

Biotricity Management Efficiency

The company has return on total asset (ROA) of (0.8862) % which means that it has lost $0.8862 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (41.0079) %, meaning that it created substantial loss on money invested by shareholders. Biotricity's management efficiency ratios could be used to measure how well Biotricity manages its routine affairs as well as how well it operates its assets and liabilities.

Compare Biotricity to Peers

Biotricity currently holds 23.88 M in liabilities with Debt to Equity (D/E) ratio of 6.45, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Biotricity has a current ratio of 1.51, which is within standard range for the sector. Note, when we think about Biotricity's use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives			EXECUTIVE Age
	Gordon JD	SurModics	62
	Taylor Ocasio	Tela Bio	N/A
	Gordon Weber	SurModics	61
	Andrew Cormack	enVVeno Medical Corp	N/A
	Thomas Ross	MaxCyte	64
	MD MSc	Delcath Systems	57
	Ronald CPA	MaxCyte	67
	MSc MD	CVRx Inc	N/A
	Les DeLuca	Bluejay Diagnostics	N/A
	Jeremy Stigall	Clearpoint Neuro	41
	Ryan McSeveney	Bluejay Diagnostics	N/A
	Craig Palmer	CVRx Inc	47
	Corey Hancock	Nortech Systems Incorporated	N/A
	Victoria Lee	PAVmed Inc	N/A
	Paul Koehn	Inari Medical	62
	Indranil Dey	Bluejay Diagnostics	62
	Jennifer Armstrong	Tela Bio	55
	Kevin Strange	Inari Medical	N/A
	Sarah Meeks	MaxCyte	N/A
	Sandy Prietto	enVVeno Medical Corp	N/A
	Deina Walsh	Bone Biologics Corp	60

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions primarily in the United States. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. Biotricity operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 44 people. Biotricity (BTCY) is traded on NASDAQ Exchange in USA. It is located in 203 Redwood Shores Parkway, Redwood City, CA, United States, 94065 and employs 55 people. Biotricity is listed under Medical Equipment category by Fama And French industry classification.

Management Performance

	Return On Equity	-41.01
	Return On Asset	-0.89

Biotricity Leadership Team

Elected by the shareholders, the Biotricity's board of directors comprises two types of representatives: Biotricity inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Biotricity. The board's role is to monitor Biotricity's management team and ensure that shareholders' interests are well served. Biotricity's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Biotricity's outside directors are responsible for providing unbiased perspectives on the board's policies.

	Fareeha Siddiqui, Senior Solutions
	Amjad Talpur, Senior Operations
	George Nikopoulos, Director Development
	Waqaas AlSiddiq, Founder, Chairman, CEO and Executive Officer
	Amir Ali, Chief Officer
	John Ayanoglou, Chief Officer
	Andy Wong, Vice Operations
	Matt Zabel, Vice Strategy

Biotricity Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Biotricity a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

	Return On Equity	-41.01
	Return On Asset	-0.89
	Profit Margin	(1.17) %
	Operating Margin	(0.96) %
	Current Valuation	38.87 M
	Shares Outstanding	21.48 M
	Shares Owned By Insiders	48.61 %
	Shares Owned By Institutions	1.62 %
	Number Of Shares Shorted	459.95 K
	Price To Earning	(6.70) X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

BTC	Bitcoin
TRX	TRON
BNB	Binance Coin

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.

You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.

Other Consideration for investing in Biotricity Stock

If you are still planning to invest in Biotricity check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Biotricity's history and understand the potential risks before investing.

	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets
	Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk
	ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios
	Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
	Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC